AR046996A1 - Derivados de amino-pirimidinas - Google Patents
Derivados de amino-pirimidinasInfo
- Publication number
- AR046996A1 AR046996A1 ARP040104907A ARP040104907A AR046996A1 AR 046996 A1 AR046996 A1 AR 046996A1 AR P040104907 A ARP040104907 A AR P040104907A AR P040104907 A ARP040104907 A AR P040104907A AR 046996 A1 AR046996 A1 AR 046996A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- amino
- saturated
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas de dichos compuestos, el uso de dichos compuestos como médicamente y en la produccion de un efecto anti-angiogénico. Procesos para la preparacion de dichos compuestos. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), donde: R1 y R2 se seleccionan independientemente entre hidrogeno, (C1-6) alquilsulfonilo, fenil(CH2)u- donde u es 0, 1, 2, 3, 4, 5 o 6, (C1-6) alcanoilo, (C1-6) alquilo, (C1-6) alcoxicarbonilo, (C3-6)cicloalquil(CH2)x- en donde x es 0, 1, 2, 3, 4, 5 o 6, o un anillo heteroarilo de 5 o 6 miembros, o R1 y R2 junto con el átomo de nitrogeno al cual se encuentran unidos representan un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado que contiene opcionalmente otro heteroátomo seleccionado entre N o O; donde los grupos (C1-6) alquilo, (C1-6) alcanoilo y (C3-6) cicloalquilo se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre fluoro, hidroxi, (C1-6) alquilo, (C1-6) alcoxi, (C1-6)alcoxi(C1-6)alcoxi, (C1-6)alcoxi(C1-6)alcoxi(C1-6)alcoxi, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, carbamoilo, mono(C1-6)alquilcarbamoilo, di-[(C1-6)alquil]carbamoilo o -N(Rd)C(O)(C1-6)alquilo en donde Rd es hidrogeno o (C1-6) alquilo, o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, o un anillo heteroarilo de 5 o 6 miembros, donde los grupos (C1-6) alcoxi, (C1-6)alcoxi(C1-6)alcoxi y (C1-6)alcoxi(C1-6)alcoxi(C1-6)alcoxi y los grupos (C1-6) alquilo de los grupos mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, mono(C1-6)alquilcarbamoilo, di-[(C1-6)alquil]carbamoilo y/o N(Rd)C(O)(C1-6)alquilo se sustituyen opcionalmente con uno o más grupos hidroxi; donde el fenilo se sustituye opcionalmente con uno o más grupos seleccionados independientemente entre halo, (C1-6) alquilo, (C1-6) alcoxi, amino, mono(C1-6)alquilamino o di-[(C1-6)alquil]amino, donde los grupos (C1-6) alquilo y (C1-6) alcoxi se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre hidroxi, amino, mono(C1-6)alquilamino o di-[(C1-6)alquil]amino; y donde cualquier anillo heterocíclico y heteroarilo en R1 y/o R2 se sustituye opcionalmente independientemente con uno o más de los siguientes: (C1-4) alquilo, (C1-4) alcoxi, (C1-4)alcoxi(C1-4)alquilo, hidroxi, amino, mono(C1-6)alquilamino o di-[(C1-6)alquil]amino, o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, o -C(O)(CH2)z y donde z es 0, 1, 2 o 3 e Y se selecciona entre hidrogeno, hidroxi, (C1-4) alcoxi, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; y con la condicion de que cuando R1 y/o R2 es un grupo (C1)alcanoilo, luego el (C1)alcanoilo no se sustituye con fluoro o hidroxi; R3 se selecciona entre hidrogeno, (C1-6) alquilo o (C1-6) alcoxi, donde los grupos alquilo y alcoxi se sustituyen opcionalmente con uno o más grupos seleccionados entre: fluoro, hidroxi, (C1-6) alquilo, (C1-6) alcoxi, carbamoilo, mono(C1-6)alquilcarbamoilo o di-[(C1-6)alquil]carbamoilo, amino, mono(C1-6)alquilamino o di(C1-6)alquilamino, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado o un anillo heteroarilo de 5 o 6 miembros donde dichos anillo heterocíclicos y heteroarilo se sustituyen opcionalmente independientemente con uno o más de los siguientes: (C1-4) alquilo, (C1-4)alcoxi, hidroxi, amino, mono(C1- 6)alquilamino o di-(C1-6)alquilamino o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; o R3 representa un grupo NR1R2 como se define precedentemente; R4 se selecciona entre hidrogeno, (C1-6) alquilo o (C1-6) alcoxi; A representa un grupo arilo o un anillo heteroarilo de 5 o 6 miembros seleccionado entre furilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, imidazolilo, pirazolilo, tiazolilo, isotiozolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, piridazinilo, pirimidinilo, pirazinilo o 1,3,5-triazonilo; R5 se selecciona entre ciclopropilo, ciano, halo, (C1-6) alcoxi o (C1-6) alquilo, donde los grupos (C1-6) alquilo y (C1-6) alcoxi se sustituyen opcionalmente con ciano o con uno o más fluoro; n es 0, 1, 2 o 3; L se encuentra unido meta o para en el anillo A respecto del punto de union del grupo etinilo y representa -C(RaRb)C(O)N(R9)-, N(R8)C(O)C(RaRb)-, -N(R8)C(O)N(R9)-, N(R8)C(O)O-, o OC(O)N(R9)-, donde R8 y R9 representan independientemente hidrogeno o (C1-6) alquilo y donde Ra y Rb representan independientemente hidrogeno o (C1-6) alquilo o Ra y Rb junto con el átomo de carbono al cual se encuentran unidos representan (C3-6) cicloalquilo; B representa un anillo (C3- 7) cicloalquilo, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, un grupo arilo, un anillo heteroarilo de 5 o 6 miembros seleccionado entre furilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, imidazolilo, pirazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, piridazinilo, pirimidinilo, pirazinilo o 1,3,5-triazonilo, o un grupo bicíclico de 8, 9 o 10 miembros el cual contiene opcionalmente 1, 2, 3 o 4 heteroátomos seleccionados independientemente entre N, O y S y el cual es saturado, parcialmente saturados o aromático; R6 se selecciona entre halo, ciano, oxo, un anillo (C3-7) cicloalquilo, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado -S(O)p-(C1-6)alquilo donde p es 0, 1 o 2, -N(Ra)C(O)(C1-6)alquilo en donde Ra es hidrogeno o (C1-6) alquilo; o R6 se selecciona entre (C1-6) alquilo o (C1-6) alcoxi, donde los grupos (C1-6) alquilo, -S(O)p-(C1-6)alquilo y (C1-6) alcoxi se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre ciano, fluoro, hidroxi, (C1-6) alcoxi, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, un anillo(C3-7) cicloalquilo o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; donde el anillo (C3-7) cicloalquilo y anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado se sustituyen opcionalmente independientemente con uno o más grupos seleccionados entre (C1-6) alquilo; y m es 0, 1, 2 o 3; y cuando B es un anillo (C3-7) cicloalquilo o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado o un grupo bicíclico de 8, 9 o 10 miembros saturado o parcialmente saturado, los anillo y el grupo bicíclico llevan opcionalmente 1 o 2 sustituyentes oxo o tioxo; y sales, prodrogas o solvatos del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0330001A GB0330001D0 (en) | 2003-12-24 | 2003-12-24 | Compounds |
GB0416850A GB0416850D0 (en) | 2004-07-29 | 2004-07-29 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046996A1 true AR046996A1 (es) | 2006-01-04 |
Family
ID=34712716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104907A AR046996A1 (es) | 2003-12-24 | 2004-12-27 | Derivados de amino-pirimidinas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080027076A1 (es) |
EP (1) | EP1737462B1 (es) |
JP (1) | JP2007517006A (es) |
AR (1) | AR046996A1 (es) |
AT (1) | ATE402705T1 (es) |
DE (1) | DE602004015509D1 (es) |
ES (1) | ES2309591T3 (es) |
HK (1) | HK1102045A1 (es) |
TW (1) | TW200524607A (es) |
UY (1) | UY28700A1 (es) |
WO (1) | WO2005060969A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410913B (de) * | 2001-08-14 | 2003-08-25 | Schelling Anlagenbau Gmbh | Auflagetisch für eine trennsäge mit einem maschinentisch |
EP1737463B1 (en) * | 2003-12-24 | 2008-12-03 | AstraZeneca AB | Pyrimidines with tie2 (tek) activity |
US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
WO2006082373A1 (en) * | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
EP1846399A1 (en) * | 2005-02-01 | 2007-10-24 | AstraZeneca AB | Pyrimidine compounds having tie2 (tek) inhibitory activity |
GB0502418D0 (en) * | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
WO2006103449A2 (en) * | 2005-03-31 | 2006-10-05 | Astrazeneca Ab | Saminopyrimidine derivates with tie2 inhibiting activity |
SI2495016T1 (sl) * | 2005-12-23 | 2020-04-30 | Ariad Pharmaceuticals, Inc. | Biciklične heteroarilne spojine |
AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
AU2013201243A1 (en) * | 2005-12-23 | 2013-03-28 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
CN101389338B (zh) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
AU2007249924B2 (en) | 2006-05-08 | 2013-07-04 | Ariad Pharmaceuticals, Inc. | Acetylenic heteroaryl compounds |
EA200870515A1 (ru) * | 2006-05-08 | 2009-06-30 | Ариад Фармасьютикалз, Инк. | Моноциклические гетероарильные соединения |
EP2022785A1 (en) | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
CA2729012A1 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
UY32009A (es) | 2008-07-29 | 2010-02-26 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas |
JP5590040B2 (ja) | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
CA2815506C (en) | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
EP3169671B1 (en) * | 2014-07-17 | 2019-08-21 | Sunshine Lake Pharma Co., Ltd. | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)urea derivatives and related compounds as flt3 inhibitors for treating cancer |
US10870647B2 (en) | 2016-06-20 | 2020-12-22 | Daegu-Gyeongbuk Medical Innovation Foundation | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer |
CA3069773A1 (en) | 2017-07-13 | 2019-01-17 | North & South Brother Pharmacy Investment Company Limited | Salt of substituted urea derivative and use thereof in medicine |
WO2020013531A1 (ko) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
JP7162931B2 (ja) | 2018-07-17 | 2022-10-31 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのアルキニル(ヘテロ)芳香族化合物 |
EP4105217A4 (en) * | 2020-02-28 | 2023-09-06 | Daegu-Gyeongbuk Medical Innovation Foundation | 3-((8-(1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A PYRIDINE-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION USING IT AS AN ACTIVE INGREDIENT |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02008240A (es) * | 2000-02-25 | 2002-11-29 | Hoffmann La Roche | Moduladores del receptor de adenosina. |
DK1303495T3 (da) * | 2000-07-24 | 2010-09-20 | Krenitsky Pharmaceuticals Inc | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet |
US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
-
2004
- 2004-12-20 EP EP04806134A patent/EP1737462B1/en not_active Not-in-force
- 2004-12-20 US US10/596,740 patent/US20080027076A1/en not_active Abandoned
- 2004-12-20 AT AT04806134T patent/ATE402705T1/de not_active IP Right Cessation
- 2004-12-20 JP JP2006546305A patent/JP2007517006A/ja active Pending
- 2004-12-20 ES ES04806134T patent/ES2309591T3/es active Active
- 2004-12-20 WO PCT/GB2004/005332 patent/WO2005060969A1/en active IP Right Grant
- 2004-12-20 DE DE602004015509T patent/DE602004015509D1/de not_active Expired - Fee Related
- 2004-12-23 UY UY28700A patent/UY28700A1/es not_active Application Discontinuation
- 2004-12-24 TW TW093140595A patent/TW200524607A/zh unknown
- 2004-12-27 AR ARP040104907A patent/AR046996A1/es unknown
-
2007
- 2007-06-25 HK HK07106766A patent/HK1102045A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1102045A1 (en) | 2007-11-02 |
EP1737462A1 (en) | 2007-01-03 |
TW200524607A (en) | 2005-08-01 |
EP1737462B1 (en) | 2008-07-30 |
ES2309591T3 (es) | 2008-12-16 |
WO2005060969A1 (en) | 2005-07-07 |
ATE402705T1 (de) | 2008-08-15 |
JP2007517006A (ja) | 2007-06-28 |
DE602004015509D1 (de) | 2008-09-11 |
UY28700A1 (es) | 2005-07-29 |
US20080027076A1 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046996A1 (es) | Derivados de amino-pirimidinas | |
AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
AR046795A1 (es) | Derivados de 2-amino-pirimidinas | |
AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
AR064619A1 (es) | Derivados de amino-imidazopiridinas, composiciones farmaceuticas que los contienen y usos de los mismos como agentes antitumorales. | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR064505A1 (es) | Derivados ester o amida de imidazolilo, composiciones farmaceuticas que los comprenden,proceso de preparacion, y usos como medicamentos para el tratamiento de enfermedades inflamatorias, entre otras. | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
EA201000413A1 (ru) | Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида | |
AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
NO20085216L (no) | Benzimidazoler og deres anvendelse i behandlingen av diabetes | |
NI201000011A (es) | Derivados de pirimidina 934. | |
CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
AR057461A1 (es) | Derivados de pirazol, proceso de preparacion, composiciones farmaceuticas y usos | |
AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |